Relay Medical Congratulates Glow LifeTech Corp. For Its Listing on the CSE Under Ticker "GLOW"

Toronto, Ontario--(Newsfile Corp. - March 15, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) ("Relay" or the "Company") would like to congratulate Glow LifeTech Corp ("Glow") for its recent listing on the Canadian Securities Exchange ("CSE"). Glow commenced trading on the CSE today under the ticker symbol "GLOW".

Relay is a founding shareholder of Glow and recently added to its position by participating in Glow's RTO financing on February 9, 2021, which was oversubscribed at over $5.1 million raised. Glow has benefitted from Relay's infrastructure, technical expertise and business leadership for the research, vetting and product validation of Glow's innovative technology.

Based in Toronto, Glow is a biotechnology company focused on powering the next generation of natural health products with highly effective, science backed natural ingredients. Glow produces nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness using its groundbreaking, plant-based MyCell^TM Technology delivery system.

"Relay is very proud to see Glow achieve this important milestone and become their own public company," said Yoav Raiter, CEO, Relay Medical Corp. "Glow has been relentless in their mission to bring scientifically-validated products to market, and we believe they are well-positioned to disrupt the marketplace with products like their recently announced ArtemiC^TM which showed promising clinical trial results with COVID-19 patients."

Glow recently announced it secured exclusive North American and Caribbean sales and distribution rights to ArtemiC™, a natural health product based on Glow's MyCell™ Technology which recently reported successful results from a COVID-19 Phase II clinical trial (see Relay's release dated Jan 14, 2021).

For more information about Glow contact ir@glowlifetech.com or subscribe to their mail list at https://www.glowlifetech.com/news.

SUBSCRIBE: For more information on Relay or to subscribe to the Company's mail list visit: https://www.relaymedical.com/news.

About Glow LifeTech

Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. Glow has rights to the groundbreaking, plant-based MyCell^TM Technology delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates, unlocking the full healing potential of natural active compounds.

Website: www.glowlifetech.com

About Relay Medical Corp.

Relay Medical is a technology developer and innovator headquartered in Toronto, Canada focused on the development of novel technologies in the diagnostics and AI data science sectors.

Website: www.relaymedical.com

Contact:
W. Clark Kent
President
Relay Medical Corp.
Office. 647-872-9982 ext. 2
TF. 1-844-247-6633 ext. 2
investor.relations@relaymedical.com

Bernhard Langer
EU Investor Relations
Office. +49 (0) 177 774 2314
Email: blanger@relaymedical.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the commercialization plans for the technology described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/77283